About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

3 Healthcare Stocks Skating on Thin Ice

By: StockStory

OMCL Cover Image

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 6.3%. This performance is a noticeable divergence from the S&P 500’s 5.1% return.

While some businesses have durable competitive advantages that enable them to grow consistently, the odds aren’t great for the ones we’re analyzing today. Taking that into account, here are three healthcare stocks we’re steering clear of.

Omnicell (OMCL)

Market Cap: $1.78 billion

Founded in 1992, Omnicell (NASDAQ: OMCL) provides automation solutions for pharmacies and healthcare providers, with a focus on improving medication management, operational efficiency, and patient safety.

Why Do We Think OMCL Will Underperform?

  1. Customers postponed purchases of its products and services this cycle as its revenue declined by 7.4% annually over the last two years
  2. Incremental sales over the last five years were much less profitable as its earnings per share fell by 9.6% annually while its revenue grew
  3. Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned

Omnicell is trading at $39.87 per share, or 21.4x forward price-to-earnings. If you’re considering OMCL for your portfolio, see our FREE research report to learn more.

NeoGenomics (NEO)

Market Cap: $1.26 billion

Founded in 2001, NeoGenomics (NASDAQ: NEO) provides genetic and molecular testing services to support cancer diagnosis and treatment decisions, specializing in clinical testing, molecular oncology, and pharmacogenomics (impact of genes on drugs and vice versa).

Why Should You Sell NEO?

  1. Issuance of new shares over the last five years caused its earnings per share to fall by 20.3% annually while its revenue grew
  2. Negative returns on capital show management lost money while trying to expand the business, and its falling returns suggest its earlier profit pools are drying up
  3. Short cash runway increases the probability of a capital raise that dilutes existing shareholders

NeoGenomics’s stock price of $9.82 implies a valuation ratio of 48.8x forward price-to-earnings. Check out our free in-depth research report to learn more about why NEO doesn’t pass our bar.

Select Medical (SEM)

Market Cap: $2.38 billion

Founded in 1996, Select Medical (NYSE: SEM) operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers across the US.

Why Does SEM Fall Short?

  1. Declining admissions over the past two years imply it may need to invest in improvements to get back on track
  2. Estimated sales decline of 17.4% for the next 12 months implies a challenging demand environment
  3. Free cash flow margin dropped by 11.5 percentage points over the last five years, implying the company became more capital intensive as competition picked up

At $18.65 per share, Select Medical trades at 16x forward price-to-earnings. Dive into our free research report to see why there are better opportunities than SEM.

Stocks We Like More

With rates dropping, inflation stabilizing, and the elections in the rearview mirror, all signs point to the start of a new bull run - and we’re laser-focused on finding the best stocks for this upcoming cycle.

Put yourself in the driver’s seat by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.

Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Axon (+711% five-year return). Find your next big winner with StockStory today for free.

More News

View More
Carmakers Step in With Incentives as EV Tax Credit Expires
Via MarketBeat
Topics Economy Government
Tickers F GM TSLA
Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure
Via MarketBeat
Topics Lawsuit
Tickers ZG
Don’t Miss These 3 Hidden Aerospace Gems Before They Take Off
Via MarketBeat
Tickers DCO EH ERJ EVEX JOBY
AI Meets Nuclear: Palantir’s Role in Energy Expansion
Via MarketBeat
Topics Artificial Intelligence Government
Tickers CEG MSFT OKLO PLTR
3 High P/E Stocks Justified by Future Upside Potential
Via MarketBeat
Tickers ONON ROKU SPOT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.